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Abstract

Diabetes is a chronic disease that occurs in the body when the pancreas fails to either
produce insulin (TID) or does not effectively use the insulin produced (TIID) and poses further
health complications as well as an insurmountable economic impact.[1] Type I diabetes is an
autoimmune disease characterized by a deficient amount of insulin production on account of the
body’s immune system destroying its own β-cells.[2] Current diabetes treatment methods include
the administration of insulin via injections or islet transplantation therapy. However, although
both are viable options, they come with limitations that make the managing of this disease
difficult. It is thus evident that there is a major need for the development of a treatment therapy
that is quicker and does not pose much adverse effects on the patient. The purpose of this
research project was to see if alpha cells can be transdifferentiated into beta cells when
undergoing mechanical stress (bioprinting) as opposed to transdifferentiating alpha cells into
beta cells without any added stress (non-printed). In this study, we demonstrated that bioprinted
cells produced insulin when exposed to glucose after having undergone the transdifferentiation
protocol as compared to cells that had not been subjected to the mechanical stress of the
bioprinter. By successfully differentiating α-cells into β-cells, we may pave a path for an
alternative cell therapy treatment method that can be used to treat diabetic patients in a health
care setting as a means of improving patient’s health and quality of life.
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Chapter 1: Introduction and Literature Research

1.1 Diabetes
Diabetes is a chronic disease characterized by elevated levels of glucose in the blood
(hyperglycemia) affecting over 463 million people worldwide.[3] This disease is often a result of the
pancreas failing to produce enough insulin or the body not being able to use the insulin that is
produced to effectively regulate blood glucose levels. There are several types of diabetes that can be
divided into type I (insulin dependent), type II (non-insulin dependent), and gestational diabetes.[4]
Type II diabetes is usually a result of the body’s inability to use the insulin that is produced by the
pancreas. This diabetes is a direct culprit of excess body weight and physical inactivity in individuals,
which is becoming a problem worldwide as more people’s diets and daily habits are changing to more
sedentary lifestyles, including children as well. Type II diabetes can usually be corrected by changing
daily habits such as diet and exercise.[5] In contrast, type I diabetes is a chronic condition that is not a
direct result of health habits. Rather, there are different factors that can contribute to type I diabetes,
to include genetics, the exposure of viruses, and other environmental factors. There is no cure for this
type of diabetes, so it must be treated for as long as the patient is alive through the management of
blood sugar levels with insulin and adhering to a healthy lifestyle to avoid possible complications.[6]
A third type of diabetes is known as gestational diabetes that is diagnosed during pregnancy due to the
irregularities of hormones changing the way your body processes sugar levels. Although gestational
diabetes poses a health threat to the mom and fetus, it usually goes away after delivery and can be
managed through a healthy diet, proper exercise, and medication if necessary.[7] All three types of
diabetes pose a threat to the public since diabetic prevalence has been rising steadily across the globe.
However, due to the nature of our research, we will be focusing on Type I (insulin dependent)
diabetes throughout our paper.
1

1.2 T1D Mechanism of Disease/ Pathogenesis
Type I diabetes is an autoimmune disorder that is characterized by deficient insulin production
which can be attributed to the body’s auto destruction of pancreatic β-cells.[8] These β-cells are
located inside the pancreas where they are responsible for the production of insulin – a “key regulator
of glucose homeostasis.”[2] The pancreas is a gland that is part of the digestive system whose main
role is converting any food that is consumed into fuel for the body.[20] This gland has two
populations of cells: exocrine cells and endocrine cells – both with different physiological functions
within the body. The endocrine cells are made up of five different hormone secreting cells that
aggregate and form the islets of Langerhans.[10] Among these aggregates, both β-cells and α-cells –
which secrete insulin and glucagon into the bloodstream, respectively – can be found. Since Type I
diabetes is characterized by a loss of β-cell mass (approx. 70 – 100%) and subsequent insulin
production, the main strategy for treating this form of diabetes is through the restoration of previously
destroyed pancreatic β-cells through cell therapy.[11]

1.3 Diabetes Therapy Treatment
There are currently two proposed therapies for restoring β-cells loss: islet transplantation and
α—cell to β-cell transdifferentiation. Islet transplantations occur when islets are taken from a donor
and they are purified to then be transferred into a person with type I diabetes. This experimental
therapy treatment has been a standard of care for diabetic patients because it decreases the need for
insulin injections and provides patients with protection from severe hypoglycemia for a prolonged
period.[12] However, there are also several downsides that possess a big risk for the patients. One of
these cons involves the risks associated with the transplant procedure itself, since the patient may be
subject to hemorrhaging, blood clotting, or subject to the severe side effects of immunosuppressive
treatments.[13] Other negative downfalls of this therapy treatment is due to a shortage of islet cells.
2

Since islets make up for less than 2% of cells within the pancreas, most of the tissue becomes waste
after transplantation.[14] Of the small percentage of cells that can be isolated for treatment, β-cells are
subject to being rejected by the body’s immune system.[13] On a molecular scale, diabetes also
influences the gene expression of the transplanted cells that then induce β-cell dysfunction and
contribute to the deterioration of β-cell differentiation. [15, 16]

An alternative therapy treatment for patients with type I diabetes is known as
transdifferentiation. Transdifferentiation is a process whereby a differentiated cell is converted into
another type of cell.[17] As mentioned above, this alternative is a cell replacement therapy method
that is increasing in popularity and further research is being done to better understand the
development of β-cell reprogramming from other existing cells in the pancreas such as α—cells,
another endocrine cell.[18] Since β-cells possess limited potential for regeneration in adult humans,
pancreatic α-cells may represent a promising source of β-cells owing to several reasons. α-cells
develop similarly to β-cells, their location in the pancreatic islet, the fact that they commonly undergo
hyperplasia in diabetic animals and patients, and the finding that a significant decrease in α-cells in
mice does not affect normal glucose metabolism.[20] Although both in vivo and in vitro research have
proven to be successful, this therapy method has yet to be translated into human clinical trials.
Another risk that α—cell to β-cell transdifferentiation has shown to possess is that undifferentiated βcells present intrinsic tumorigenic properties that can pose a risk to the subject.[21] Whereas this
method seems to pose a great functional alternative to address the β-cell deficit in type I diabetes, the
limited knowledge of “basic processes that control differentiation, proliferation, survival, and
physiology of β-cells,”[22] remain unsatisfactory since they still don’t offer a cure or sufficient
mitigation in preventing the complications associated with type I diabetes.

3

1.4 α and β cell growth factors
Alpha (α) and beta (β) cells produce glucagon and insulin, respectfully, and employ counterregulatory actions on glucose metabolism. By stimulating glycogenolysis and gluconeogenesis,
glucagon is directly responsible for increasing glucose levels in the body. Similarly, β-cells secrete
insulin that then decrease glucose levels in the body by prompting glucose storage in cells and
simultaneously lowering the total body glucose secretion.[23] Both alpha and beta cells rely on each
other to modulate their activities and maintain a healthy glucose level balance from within the body,
since insulin represses glucagon expression/release from α-cells while glucagon stimulates β-cell
insulin secretion.[24] Both cells’ functions are so dependent of each other that Morgan, L. Y., et al.
2015 showed that glucagon gene activation is responsible for α-cell fate switch since the blocking of
glucagon signaling pathway leads to an immense decrease in β-cell regeneration.[23] As observed in
this study, data supports a model where the glucagon/GLP-1 signaling pathway works to elicit β-cell
formation from previous α-cells since peptides derived from glucagon genes are crucial for the
regulation of this endogenous repair system, suggesting that possible further stimulation of
transdifferentiation might lead to a successful and efficient cell replacement therapy in
humans.[23,25, 31] Although glucagon is a primary acting hormone aiding in β-cell differentiation,
there are other growth factors and transcription factors that further drive this eventual cell
differentiation. One such example is Urocorin3 (Ucn3) which is a protein encoding gene and member
of corticotropin-releasing factor/ urotensin I family that helps generate the mature peptide hormone
that is then secreted by both α and β cells and helps regulate insulin secretion via response to glucose
levels in the plasma. As a result, Ucn3 acts as a marker of β-cell maturation as it is found in the
intermediate stage of α-cell to β-cell transdifferentiation.[10] Other factors heavily influencing this
transdifferentiation include Pdx1 and MafA expression among others. These transcriptional factors
are crucial in β-cell development and maturation after initial transdifferentiation process, of which
4

Pdx1 remains a relevant insulin promoter factor throughout the β-cell’s life, and aids in the activation
of transcriptional insulin genes.[18, 19]

Image 1.4: Imagine highlights transcriptions factors found at different stages of the pancreatic cell lineage. As observed in the image, it also highlights
the transcription factors playing a role in the process of α to β cell transdifferentiation.

1.5 Thermal Inkjet Bioprinter (TIB)
A relatively novel research method that has proven to be groundbreaking in several research fields
such as tissue engineering and medicine is known as cell-printing, or bioprinting.[25, 27] Being still
in its infancy stage for biological applications, bioprinting can be defined as the depositing of cells
and other biomaterials in “precise spatial arrangements to enhance cell-cell arrangement and
communication.”[26] Currently, there are three main types of bioprinters (inkjet, microextrusion, and
laser-assisted printing) which all involve heat generation that may cause a physiological and
biochemical alteration to cells after having been printed. There are two methods used to form the
5

drops of ink known as continuous inkjet printing (CIJ) and drop on demand (DOD) printing.[28]
Whereas CIJ charges the drops as they form to then be steered into location by electric or magnetic
fields, the DOD method focuses on producing drops and placing them in position by hovering the
drop generator above the desired position.[28] For the purpose of our experiment, we worked with the
DOD method using a Thermal Inkjet Bioprinter (TIB). This bioprinting process exerts a thermal force
on the cells, leading to alterations in the cells. At the beginning of the printing process, the thermal
actuator/ resistor of the ink cartridges heats up to 300°C which then disperses into the bioink that will
be printed and increases the overall temperature of the sample. This heat increase causes the bio-ink
bubbles to form on the surface of the resistor. Eventually, enough pressure is exerted on the resistor,
the bubbles overcome this surface tension, and bioink droplets containing cells are “printed” into the
surface plate at the bottom of the printer.[29] With bioprinting being a relatively novel bio-fabrication
process, there is minimal information available providing a clear image of the direct effects that it
poses into the printed cells due to the temperature change as well as the stress they are subjected to.
As a result, it is possible for these cells to undergo extreme mechanical and heat stressors that, given
the right circumstances and experimental protocol, will allow for fully physiological alterations that
will then allow us to manipulate printed cells in novel ways.

1.6 ELISA Immunoassays
ELISA Immunoassays are procedures utilized in a lab setting to quantitively measure specific
antigens in a sample through the binding of antibodies and proteins. By immobilizing the reactants to
the microplate surface, we are able to wash away any non-bound material from the cell whilst leaving
specific analytes for measuring. All ELISA assays contain the same elements which start with the
direct immobilization of antigens to the surface of the wells along with the addition of irrelevant
proteins to cover unsaturated surface-binding sites of the wells. After the initial coating, the next step
6

is to incubate the wells with antigen specific antibodies that successfully bind to the antigens. Once
removing all of the unbound material from the wells, we can quantitatively measure the signal
generated from the specific antibodies in the sample using instrumentation such as a
spectrophotometer, a fluorometer, or even a luminometer. Currently, there are different ELISA
formats which can be categorized as direct, indirect, sandwich, and competitive ELISA detection
methods. Direct ELISA assays involve the direct immobilization of the antigen onto the plate while
the conjugated detection antibody then binds to the target protein. The substrate added then produces
a signal that is proportional to the amount of analyte in the sample (direct correlation). A second type
of ELISA assay is the indirect ELISA which is similar to the direct ELISA assay. However, this assay
includes an additional amplification detection step in the form of a conjugated secondary antibody
directed against the host species of the primary antibody for which the substrate then produces a
signal that is, again, proportional to the amount of antigen bound in the well. The third and most
common type of ELISA assay used is the sandwich ELISA which is used to determine the analyte
concentration in a sample. In this assay, two specific antibodies are used to sandwich the antigen.
First, the microplate is covered in capture antibodies which are then bound to the protein or antigen of
interest and become immobilized. A secondary antibody is then added to bind to the target protein, in
a sandwich manner, and the substrate that is added to the sample emits a signal proportional to the
amount of analyte present in the sample. This type of ELISA is most used because the two antibodies
required make this assay highly specific.[30]

7

Image 2: Diagram offers a visual of the three different kinds of ELISA assays for comparison. Direct and indirect assays are characterized by the binding
of the antigen directly to the plate surface and then having the antibody conjugate(s) of interest attach to the antigen. By contrast, the sandwich assay first
binds the capture antibody to the plate surface. The antigen is then bound to this first capture antibody followed by the secondary antibody, entrapping
the antigen in a “sandwich” manner.
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1.7 Research goal and Significance
Our research goal is primarily focused on determining if there is a success rate of
transdifferentiation of α-cells into β-cells when placed under the biomechanical stress of bioprinting
as opposed to transdifferentiation into β-cells without having undergone a biomechanical stress
beforehand. With diabetes being one of the major causes of death worldwide, a breakthrough in this
research field would pose great significance. Not only would it greatly impact the world’s economy in
a positive manner, but it would also help increase the quality of care in patients in healthcare settings
whilst monumentally improving the quality of life for type I and type II diabetic patients.
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Chapter 2: Materials and methods

2.1 Reagents
This research is primarily focused on the transdifferentiation of β-cells from α-cells to
successfully produce insulin. As a result, a variety of reagents will be used during the research
project. For cell differentiation, we used several growth factors aimed at promoting cell proliferation
and ensuing better cell survival from environmental stress as well as supporting cell differentiation. A
more detailed overview and description of these GF can be observed on Table 1 in the index.
The cell fixing method used reagents aimed at preserving cells and structures (4%
paraformaldehyde) while cell staining relied on reagents, used to pull out cell structures and proteins
(Triton X-100), and a blocking buffer to use with specific primary and secondary antibodies that
bound to cell structures for staining (a detailed chart of the antibodies used can be found on Table 2 in
the index). Other reagents used for this protocol include phosphate-buffer saline (PBS) to wash the
cells of excess reagents, 1% bovine serum albumin (BSA) in PBST for use with antibodies, and DAPI
solution - a dye used to fluorescent DNA staining.
The final ELISA insulin assay relied on reagents who focused on quantitatively measuring the
insulin production of both experimental cell samples and mouse insulin. For this assay we used the
Crystal Chem® Ultra Sensitive Mouse Insulin ELISA Kit (Catalog#: 90080) ordered from Crystal
Chem High Performance Assays. The reagents in this kit included the mouse insulin stock solution (to
make the insulin standard), the anti-insulin enzyme conjugate, an enzyme substrate solution along
with the enzyme reaction stop solution, a sample diluent, and a wash buffer.

10

2.2 Cell culture and seeding
For this project, pancreatic mouse alpha TC1 cell clone 6 (ATCC® CRL – 2934) were used.
These cells were grown in DMEM, low glucose medium which was supplemented with 10% FBS, 12
mM HEPES, 0.1 mM amino acids, and 0.02% bovine serum albumin. The cells were then kept in the
incubator at a temperature of 37˚C with a 10% carbon dioxide continuous flow until they were ready
to be passaged.
To seed the cells, they were first thawed out and placed in a centrifuge tube along with 10 mL
of DMEM media. The centrifuge tube was then centrifuged for 5 min at 2000 RPM until the cells
formed a pellet in the bottom. Next, the supernatant was removed from the tube (to remove DMSO
and trypsin) and 1 mL of α—cell media was added to mix with the cells. The 1 mL mixture of cells
and media was then pipetted into a T-75 cell flask along with another 14 mL of α-cell media which
was then placed into an incubator chamber. In order to keep the DMEM media fresh for the cells, the
first media change was done 24h after the first seeding and then every other day subsequently until
cell confluency was enough for splitting.

2.3 Cell printing
Cell printing is the most critical part of the project, which is done after performing the cell
splitting protocol to isolate the cells from the DMEM media through centrifugation. For this project,
we utilized a readily available modified HP inkjet bioprinter since we were going to be working with
the DOD method to place cells directly into the wells. We decided to use this kind of bioprinter since
previous research had proven to be successful and, while cells were stressed sufficiently, it did not
induce any major harm or apoptosis on these cells. Once the supernatant was removed, 2 mL of PBS
was placed in the tube to break the cell pellet and ensure an even distribution of suspended cells for
printing. Before pipetting cells into the printer cartridge, make sure the printer is set up and working
11

correctly (a test run with milli-Q water is strongly advised to accurately measure placement and DOD
printing). Pipette 150 µL of the cell suspension into the cartridge and run the program to print the
cells into a 96 – well cell – adhering plate at the desired rate and time (as shown on Image 3.3 below)
and label as “printed experimental group.” Along with the printed cells, transfer 12 µL of non-printed
cells into another 12 designated wells on cell – adhering plate (again, shown on Image 3.3) and label
as “non-printed control group.” Add 75 µL of “day 1” differentiation media into all 24 wells and
place in incubator (37°C and 10% CO2) for continued cell growth. Continue β-cell differentiation
protocol as stated by protocol guidelines.

Image 3.3: Image shows the 96 – well cell distribution and how the different experimental and control groups were placed in the plate. As shown
above, the red wells were the printed cells while the gray wells were the non-printed cells. These groups would be undergoing the β-cell
differentiation protocol. The wells at the bottom (navy blue) represent the control group, which are the α-cells that did not undergo the
differentiation protocol.
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2.4 Cell differentiation
Cell differentiation was conducted at the same time every day for at least 21 days (minimal
duration of protocol). The protocol was divided into 6 different stages where each stage varied with
different factors to promote β-cell differentiation from the preliminary printed α-cells. Following the
protocol, media changes were done either every day or every other day. These media changes,
performed inside a safety hood to prevent contamination, were carefully done with a micropipette to
remove all the liquid in the wells, adding 100 µL of the appropriate media to the wells and finally
placed in the incubator again to keep promoting cell differentiation. A detailed overview of the β-cell
differentiation protocol can be found on Table 2 in the index.

2.5 Cell fixation
Having finished the cell differentiation stage, cells needed to be fixed into the plate before
staining to freeze cellular proteins and structures in place for later microscope observation. This fixing
protocol is done with all solutions warmed up to 36°C and under a biohazard hood to prevent any
health hazards. As shown in Image 3.5 below, we fixed the first three wells from each group (colored
in sky blue) while the other wells would be preserved for further experiments.

13

Image 3.5: Image displays the 96-well plate and its cell fixing/ staining distribution. Three wells from each experimental and control group were
fixed and scanned for differentiated β-cells under the confocal microscope.

First, the medium inside the wells that would be fixed/ stained were aspirated – careful not to aspirate
the cells as well or scratch the bottom of the well. Each well was then rinsed with PBS and then 100
µL of 4% paraformaldehyde solution was added for 20 minutes. In the final stage, we removed the
paraformaldehyde and rinsed the wells with PBS. Due to time constraints, we were not able to
continue with the cell staining that same day. As a result, we filled each well with 100 µL of PBS and
stored in the incubator to preserve the cells that had not been fixed in the other wells. We worked in
triplicate to fix cells – where we fixed three wells from each group that where then going to be
followed by the staining process.

14

2.6 Cell staining
Cell staining is done to have a better visual of cells and its components when seen under a
microscope. This method was done after fixing the cells in the wells. Since the fixed cells were being
hydrated by PBS, the first step was to aspirate the 100 µL of PBS and add another 100 µL of Triton
X-100 to each well for 10 minutes. The Triton X-100 was then removed, and the wells were rinsed 3x
with PBS, waiting 5 mins in between rinses to remove any residual Triton X-100. After these 3 initial
washes, 100 µL of blocking buffer (composed of 1% BSA, 22.52 mg/mL glycine in PBST (PBS+
0.1% Tween 20) was added to each well for 30 minutes, followed by a 5-minute PBS wash. We then
incubated the cells in 50 µL 1% BSA in PBST along with 1 µL of diluted antibody (1:50 dilution)
inside the incubator for 1 hour. This first antibody that we used were 3 different primary antibodies
that were placed once in each well of the individual groups, which included an antibody for PDX1,
glucagon antibody, and NKX6-1 antibody. This solution was subsequently aspirated and kept in
conical tubes for later use while the cells were once again washed 3x in PBS for 5 minutes each time.
The cells were incubated again with a 1:50 dilution of 1 µL of a second primary antibody (Anti-C
peptide) in 50 µL 1% BSA solution in PBST for 1 hour at room temperature in the dark. The solution
was again preserved while the cells were once again washed 3x with PBS for 5 minutes. Thirdly, we
incubated the cells a third time with 1 µL of a secondary antibody (Goat anti-rabbit igG) in 50 µL 1%
BSA in PBST for 1 hour (1:50 dilution) and subsequently washed the cells 3x with PBS for 5
minutes, making sure we saved the antibody supernatant as well. We treated the cells with 1 µL of
second secondary antibody (Goat anti-mouse IgG) in 50 µL of 1% BSA in PBST (1:50 dilution) and
incubated for 1 hour, followed by the washing of the cells 3x with PBS for 5 minutes each wash. To
finalize the cell staining protocol, we added 50 µL of DAPI to each well and waited for 30 minutes.
After a final cell wash with PBS (3x for 5 minutes each), the cells were ready to be imaged using the
confocal microscope to determine if there had been any β-cell differentiation from the α-cells.
15

Note: After cells have been fixed and stained, they should be hydrated with PBS. These cells can then
be maintained for months and imaged later.

2.7 Mouse insulin assay
This assay is performed for the quantitative determination of insulin produced in the cell
culture media from our experiment. To have a more precise and accurate measurement of the insulin
production of our wells, it was important to first prepare a mouse insulin standard curve that would
graphically show the relationship between the insulin concentrations and the absorbance of a light
wavelength. For this standard curve, we first prepared all the reagents we were going to use as
specified by the manual. Making sure to use polypropylene microtubes since they have minimal
adsorption of insulin, we first pipetted 150 µL of sample diluent and mixed it with 50 µL of the
mouse insulin stock solution (25.6 ng/mL) inside a microtube labeled 6.4ng/mL. From this first tube,
we micropipetted 50 µL of the sample diluent into 6 polypropylene microtubes and labeled each one
depending on the concentrations that we were going to be working with (0.1, 0.2, 0.4, 0.8, 1.6, and 3.2
ng/mL). Using the micropipette, we dispensed 50 µL of the 6.4 ng/mL sample standard into the tube
labeled 3.2 ng/mL and mixed it thoroughly. Afterwards, we took 50 µL of the 3.2 ng/mL sample and
mixed it with the sample diluent in the 1.6 ng/mL tube. We repeated this step progressively with all
the samples for the remaining 4 microtubules. Finally, to obtain a control of the standard curve line,
we pipetted 50 µL of the sample diluent into a final polypropylene microtube and labeled it as 0
ng/mL since there would not be any mouse insulin on this sample. Since the mouse curve line was
used to establish an insulin baseline and there were no experimental cells involved, we only
performed each dilution in a duplicate manner and recorded the mean reading.
After having prepared the working mouse insulin standard, we performed the assay with the
experimental glucose concentrations, which we performed in triplicates of each concentration,
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obtained the insulin values, and recorded the mean absorbance value from each insulin concentration.
These different glucose concentrations are important since the goal of the assay is to measure total
insulin production when exposed to different concentrations of glucose solutions and determine if αcells did undergo β-cell transdifferentiation. The three different glucose amounts that we worked with
were 0.009 g, 0.025 g, and 0.150 g. However, these amounts of glucose called for a 50 mL islet media
solution, and we needed a minimal amount of glucose solution (5 mL), thus changing the amount of
glucose used to 0.0009 g, 0.0025 g, and 0.015 g respectively to maintain the same concentration.
Using 3 – 15 mL conical tubes and a scale, we weighed out the powdered glucose and then mixed it
with 5 mL islet media until we had a homogeneous mixture that we then filtered out for impurities.
Our next step was to begin the assay by inducing the first reaction. After making sure all reagents and
working materials were room temperature, we removed the antibody coated microplates from their
pouch and placed them in the supporting frame where we then added 95 µL of the sample diluent in
each well that we were going to be using. Note: To eliminate any kind of incorrect absorbency
reading, every sample (for both experimental glucose concentrations and mouse insulin standards)
had to be assayed in duplicate. We then added 5 µL samples of both glucose and insulin working
standards into the wells and covered both the plate and the 96-well plate and incubated them for 2
hours at 4°C. After the two hours were up, we aspirated the contents in the wells and washed them 5x
with the provided wash buffer using 300 µL per well and removed any excess wash buffer by
inverting the plates and tapping the wells firmly onto a paper towel. Having finished all 5 washes, we
then pipetted 100 µL of anti-insulin enzyme conjugate, covered the plates once more, and incubated it
for 30 minutes at room temperature. The next step was to, once again, wash the well 7x using 300 µL
of wash buffer and remove any excess wash buffer. Following the wash, we added 100 µL of enzyme
substrate solution and let it react for 40 minutes at room temperature making sure to not expose it to
light or cover it in aluminum. After the 40 minutes were up, we stopped the mechanism of the enzyme
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substrate solution by immediately adding another 100 µL of enzyme reaction stop solution so that we
could measure the insulin production based off of the absorbency levels indicated on the samples.
Note: After adding the enzyme reaction stop solution, we had 30 minutes to measure the absorbance
of the samples before any significant change occurred in the wells.
The final step involved the use of a spectrophotometer to run the different dilution samples
that we collected, record the absorbance of light based off the insulin concentration, and create a
standard curve off the measurements to compare the mouse insulin standard vs experimental insulin
production. This step was done by first measuring the absorbency of the sample under the 430 nm
wavelength and then repeating the readings using the 630 nm wavelength and finally subtracting the
A630 readings from the A450 to obtain the values to plot into the graph.

Image 3.7: Image provides an overview of the 96 – well plate for the ELISA insulin assay. As depicted on the picture above, the progressive
darkening of color shows the different glucose concentrations (in triplicates) that the cells in each experimental group were exposed to. The lightest
green denotes a concentration of 0.00018 g/ mL while the middle triplicate has a glucose concentration of 0.0005 g/mL and the darkest green
accounts for the highest glucose concentration of 0.003 g/mL.
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Chapter 3: Results and Discussion

3.1 Confocal Microscopy Imaging
Image 3.1.1a: α-cell control
A

Image 3.1.1a: This image provides a visual of the control α-cell group under when viewed under the confocal microscope. Image A shows cells stained
with glucagon antibody.

Image 3.1.1b: α-cell control
B

Image 3.1.1a: This image provides a visual of the control α-cell group under when viewed under the confocal microscope. Image B shows cells stained
stained with DAPI blue dye.
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Image 3.1.1a and image 3.1.1b highlight two different regions taken from the control wells (αcells) as well as their morphological properties as seen through confocal microscopy using
immunofluorescence staining. Image A shows cell samples that were stained with glucagon antibody
and subsequently reacted with a secondary antibody in order to test for the presence of glucagon
production in the cells. Image B shows cells stained with DAPI blue dye which binds to the A-T
regions of dsDNA helix of live cells. This stain was done to show that the samples we were working
with were alive at the time of fixing. We also tested for insulin presence in the α-cells by staining the
wells with both PDX1 and NKX6.1 antibodies but did not find any insulin production from within
these cells. Insulin is a peptide hormone that directly affects α-cells by regulating glucagon secretion
from these cells, so it would be normal to find insulin within these cells. However, since both the
PDX1 and NKX6.1 antibodies are insulin promoter factor genes, the stain would be retained in the
cellular nucleus if the cell was producing insulin.
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Image 3.1.2: Printed cell (PDX1 antibody)
A

B

C

D

Image 3.1.2: This image provides a visual of a printed cell after having undergone the transdifferential protocol. From these images, A represents a
composite of the cell with all three dyes bound to the cell. Image B shows the cell stained with DAPI blue dye while image C was checking for the
presence of Pdx1 antibody and image D depicted the presence of C – peptide antibody in the cell.
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Image 3.1.3: (NKX6.1 antibody)

A

B

C

D

Image 3.1.3: This image provides a visual of a printed cell after having undergone the transdifferential protocol. From these images, A represents a
composite of the cell with all three dyes bound to the it. Image B shows the cell stained with DAPI blue dye while image C was checking for the
presence of Nkx6.1 antibody and image D depicted the presence of C – peptide antibody in the cell.

Image 3.1.2 shows printed cells treated with PDX1 antibodies with the C – peptide antibodies
(to check for insulin production). Whereas the glucagon antibody was used in cells to look for the
presence of glucose (i.e. alpha cells), both PDX1 and NKX6.1 were chosen for other specific reasons.
22

As cited in literature work, PDX1 was chosen as a transcription factor of interest because it is a
critical transcription factor that is present in all stages of cell differentiation/ maturation into β –
cells.[46] As opposed to Pdx1, NKX6.1 is a transcription factor that is solely found in differentiated
beta cells and can therefore help us infer that the cells successfully differentiated into β-cells.[47]
As seen on image A, a composite image is produced showing all of the dyes reacting within
the cell’s components such as proteins and hormones. Image B is the cell stained with DAPI blue
binding to the A-T regions of the dsDNA while image C portrays the binding of the primary antibody
used, PDX1 (pancreatic and duodenal homeobox 1), which is a protein coding gene that is heavily
expressed in β-cells as it encodes a transcriptional activator of genes that include insulin. This
transcription factor also plays an important role in pancreatic β-cell function and survival. During the
early stages of differentiation, it has been observed that β-cells overexpress this transcription factor to
keep stimulating cell differentiation. As it can be observed, the cell has a high concentration and green
contrast in the center of the cell which indicates there is an overexpression of PDX1 taking place in
the nucleus of the cell, further supporting the notion that the previous α-cells have undergone cell
transdifferentiation into insulin producing β-cells. Finally, image D is linked to the primary antibody
used to check for C-peptide antibody. C-peptide is a byproduct of insulin formation that takes place in
the pancreas, oftentimes being a prohormone precursor to insulin that is produced in β-cells. Usually,
higher levels of C-peptide serve as an indicator of endogenous insulin production in pancreatic islets.
As seen on image A and D, the red dye seems to expand further than the cell. This may be an
indicator that the cell is not only successfully producing insulin but that it has also begun to secrete it
to the extracellular matrix.
Similarly, image 3.1.3 shows a cell treated with NKX6.1 antibodies (instead of NKX6.1) as
well as C-peptide antibodies (to check for insulin production). As seen with the previous image,
image A utilizes DAPI blue dye to check for live cells as the dye binds to the dsDNA in live cells. For
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this image, the green dye is linked to the primary antibody NKX6.1, another transcription factor
encoding for the activation of insulin genes. The NKX6.1 transcription factor plays a crucial role in βcell function and proliferation and is exclusively found in β-cells and no other cells in the islet within
the pancreas as it inhibits glucagon gene transcription. Once again, as observed in the previous image,
there is a really high concentration and green contrast in the center of the cell which indicates the
presence of NKX6.1 transcription factor taking place in the nucleus of the cell, further supporting the
notion that the previous α-cells have undergone a cell transdifferentiation into insulin producing βcells. For this well, image D shows the red dye that is also linked to the C-Peptide antibody to check
for C-Peptide production and subsequently the production and secretion of insulin from within the
cell, which is also evident. **

** Note: Distance in shape and colors might indicate a difference in differential stages where the cell is barely starting to
produce and secrete insulin into the extracellular matrix space.
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3.2 ELISA Sandwich Assay

Further tests were performed to establish a quantitative analysis on the amount of insulin
secreted by the different experimental group of islet cells when exposed to specific glucose
concentrations.

Graph 3.2.1: Provides an overview of the Mouse Insulin Standard curve performed with the ELISA insulin assay. Standard curves are important in
experiments to ensure the precision and accuracy of the experiments performed subsequently.
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Graph 3.2.2: Portrays the values expressed as means ± SE of the insulin absorbance when exposed to increasing glucose concentrations. As noted on the
graph, some values increase while others decrease as the glucose concentration increases.

Graph 3.2.3: Provides an overview of the mean insulin production and absorbance of the control values ± SE. As seen on the graph, the mean
absorbance values for all three glucose concentrations are recorded as well as the controls for stand alone α-cells, β-cells, and PBS.
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Graph 3.2.1 logged the absorbance values of the mouse insulin standard curve (ng/mL) for
different concentration dilutions. Starting at a concentration of 0, which was simply milli-Q water, we
then recorded the two-fold increasing absorbance values all the way to 6.4 ng/mL. As seen from the
graph, there is an exponential correlation line, meaning the reading absorbances increases in relation
to the concentration values across the graph.
The second graph, graph 3.2.2, displays the mean values ± SE of the insulin absorbance levels
vs. glucose concentration levels. As shown above, we graphed the correlation of the average
absorbency values for printed, non-printed, and α-cells. From the graph, we can see that the printed
cells insulin absorbed is directly proportional to the increasing glucose concentrations, meaning that
the insulin secretion of the cells increased as it became exposed to higher amounts of glucose.
Similarly, it can also be noted that both the non-printed and α-cells shared similar characteristics
when measuring the insulin absorbance of increasing glucose concentration. Rather than a direct
increasing proportion, both experimental groups exhibited an indirect proportion where the recorded
values of insulin decreased as the glucose concentration increased. This may be attributed to the fact
that insulin production remains relatively constant as opposed to the increasing glucose concentration.
As a result, the overall insulin concentration decreases as well. Our findings point to the fact that the
cells that were printed underwent a transdifferentiation phase change to β-cells and began secreting
insulin as opposed to both the non-printed and α-cells.
Finally, graph 3.2.3 plots the average mean values for both the stand-alone glucose
concentrations as well as the control values for α-cells, β-cells, and PBS solution which are all
presented for comparison to the experimental groups. As seen above on graph 3.2.3, insulin
absorbance values slightly increase linearly as the glucose concentrations increase as well. When
comparing PBS solution to the cell lines, we can see that both the PBS and the α-cells presented
similar absorbance values while the absorbance in the β-cell control was a little bit more than double
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as compared to the α-cells. This graph serves to further support our initial hypothesis that bioprinting
α-cells would aid successfully in the transdifferentiation into β-cells. **
** NOTE: Any insulin markers found in ELISA assay where there shouldn’t be may be due to insulin precursors found in
cells/ samples or possible minimal contamination of samples when measuring absorbance values in the cuvette.
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Chapter 4: Conclusion

In conclusion, our research hypothesis was supported by the data gathered in this project as we
demonstrated that bioprinted cells were able to undergo the transdifferentiation protocol into β-cells
and secrete insulin. Due to the supporting evidence collected, it is apparent that cells endure
mechanical stress during the bioprinting process that ultimately leads to both physiological and
chemical alterations whereas non printed cells do not have the same fate and remain unaltered by the
transdifferentiation protocol. This is a significant observation since further testing and optimized
bioprinting research could lead to the potential development of an alternative cell therapy treatment
that could improve and help eradicate diabetes worldwide.
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Chapter 5: Limitations and Future work

5.1 Limitations
A limitation that can be addressed for the project involves the use of the bioprinter and the
bioprinting process. Since the DOD method relies on cartridges, some of these nozzles could lead to
becoming blocked when attempting to print cells into the wells due to cellular debris or
sedimentation. This could lead to a minimal number of cells being printed into the wells and thus
hindering the transdifferentiation process. Another limitation that was presented during the project
was the failure to further adhere the cells to the bottom of their wells in order to prevent them from
being washed away during the differentiation protocol with all the media handling and washing.

5.2 Future work
With this research being preliminary, some of the future work that must be accomplished is
the successful repeat of this project and procedure with a bigger sample size for both the printed and
the non-printed cells. This project would eventually lead to in vivo work with appropriate protocols to
ensure a controlled, successful project. Additionally, it would also be wise to investigate and promote
further research so that differentiated β-cells are not targeted by the immune system or slow the
gradual loss of their function. The ending vision for this project is to be able to successfully use
bioprinting technology to significantly promote the transdifferentiation of α-cells into β-cells and then
inject these same cells in diabetic patients as an alternative, successful therapy treatment.
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Glossary

a. Transdifferentiation – The conversion of a fully differentiated cell into another cell type.
b. Alpha (α) cells – Endocrine cells in pancreatic islets composing 20% of human islet cells and
secreting peptide hormone glucagon.
c. Beta (β) cells – Endocrine cells that make and secrete insulin.
d. Glucagon – A hormone produced by alpha cells that is involved in controlling blood glucose
levels by promoting the breakdown of glycogen to glucose.
e. Insulin – A hormone produced by beta cells that controls and allows for glucose to enter the
body’s cells for energy.
f. Confocal Microscopy – A fluorescence imaging technique that utilizes laser point source to
scan the sample.
g. IF (Immunofluorescence) – A laboratory technique based on the use of specific antibodies
conjugated to fluorescent dyes that bind to cellular antigens.
h. PBS (Phosphate-buffered saline) – A buffer solution used in biological applications such as
cell washing and transportation of tissues and dilutions.
i. PBST (Phosphate-buffered saline/Tween) – PBS with a low concentration of detergent
solution used as a wash solution that does not damage antigen/antibody complex. This solution
is commonly used in western blots or ELISA assays.
j. BSA (Bovine Serum Albumin) – A serum albumin protein used as a protein concentration
standard in labs, as a cell nutrient, and has the ability to stabilize enzymes.
k. dsDNA – double stranded DNA
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Appendix

8.1 Table 1: Transdifferentiation Growth Factors
Growth
Factor
Activin A

Purpose
A member of the TGF-β (transforming growth factor) superfamily. It is made up of two β
subunits. A cytokine with roles in inflammation regulation, fibrosis and wound
repair.[32]

CHIR99021

An aminopyrimidine derivative that is an extremely potent glycogen synthase kinase
(GSK) 3 inhibitor. Promotes self-renewal and enhances derivation efficiency of mouse
ESCs. Stabilizes β-catenin and signaling pathways such as TGF-β, Notchm and
MAPK.[33]

LDN193189

A potent inhibitor of the bone morphogenetic (BMP) pathway and its induced signaling
cascades which regulate cell fate decisions during embryogenesis.[34]

KGF
SANT-1

An epithelial cell specific mitogen secreted by stromal fibroblasts. A potent EGF in
promoting cellular proliferation and differentiation.[35]
Cell-permeable antagonist that inhibits Sonic (Shh) Hedgehog signaling pathway.
Inhibits the proliferation of glioma stem-like cells. Antagonist promotes beta cell
differentiation from human embryonic stem cells. [36]

PDBu

A protein kinase C (PKC) activator. Playing a role in the proliferation and differentiation
of various cell types.[37]

Y27632

A specific inhibitor of Rho-associated kinases (ROCK). Improves survival of human ES
cell monolayers at the initiation of differentiation protocols. [38]

RA

An analogue of vitamin A. Has a key role in cell growth and differentiation by activating
nuclear receptors. [39]

XXI

Analogue inhibitor of γ-secretases and Notch processing. Lowers Aβ levels in APP
transgenic mice [40]

Alk5
T3
Betacellulin

Small molecule inhibitor protecting cells from loss of key β cell transcription factors.
Restores mature β – cell identity after exposure to prolonged/ severe diabetes. [41]
Stimulates respiratory activity at mitochondrial level. [42]
Is a member of EGF family and plays significant role in regulating growth differentiation
of pancreatic β -cells [43]
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8.2 Table 2: Cell Staining Antibodies
Antibodies
MBS 395603
(Pdx1 antibody)
MBS 9600104
(Glucagon antibody)
MBS 9211953
(Nkx6.1 antibody)
NB 110-2554
C – Peptide antibody

NB 7159
(Goat anti-rabbit IgG)
NB 120-6786
(Goat anti-mouse IgG)
DAPI Blue

Reaction/ Purpose
Primary antibody; Insulin promoter factor 1 that is a transcriptional
activator of genes (insulin). The development of β-cells overexpresses
Pdx1 TF.
Primary antibody; Stimulates gluconeogenesis and glycogenolysis in the
cell.
Primary antibody; Transciption factor playing an important role in
pancreatic β-cell function/ proliferation. This TF is found solely in β-cells
and inhibits glucagon gene transcription.
Primary antibody; A peptide byproduct of insulin formation by the
pancreas. Released from β-cells during the cleavage of insulin from
insulin. High C-peptide molecules indicate high levels of endogenous
insulin production.
Secondary antibody; Antibodies characterized for specificity for rabbit
immunoglobulin classes, subclasses, and fragments.
Secondary antibody; Antibodies characterized for specificity for mouse
immunoglobulin classes, subclasses, and fragments.
A blue-fluorescent DNA stain exhibiting a fluorescence enhancement
when binding to the A-T regions of the dsDNA.
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8.3 Cell counting:
Cell counting is crucial for experiment success since it allows researchers to accurately assess
the cell concentration in a solution. Subsequently, we used this technique to determine the
number of cells that we were going to be plating into each well in order to ascertain an equal
number of cells.
406 / 16 = 25.1875 * 104
➔ 2.51875 * 105
➔ 2.52* 105cells per mL
For printing
150 µL of cells (into 12 wells)
→ (150 µL / 1000 µL) * (‘x’ / 2.52 * 105 cells) = 37,500 cells ≈ 3.75 * 104 cells
→ 3.75 * 104 cells / 12 wells ≈ 3.125 * 103 cells per well
For seeding
12 µL of cells per well
→ (12 µL / 1000 µL) * (‘x’ / 2.52 * 105 cells) = 3000 cells
→ ≈ 3 * 103 cells per well
α-cells
284 / 16 = 17.75 * 104
➔ 1.775 * 105
➔ 1.78 * 105 cells per Ml
α-cells control
18 µL of cells per well
→ (18 µL / 1000 µL) * (‘x’ / 1.78 *105cells) = 3,204 cells ≈ 3.2 * 103 cells
→ ≈ 3.2 * 103 cells per well
*** Incubate 96 – well plate at 37 °C ; 10% CO2 to maintain cells ***

8.4 Β – cell media formulation differentiation schedule
This procedure is spaced out over 21 days where the distinct growth factors are
implemented to promote β-cell differentiation.
Stage
Stage 1

Day

Basal
Media

Day 1

S1

Day 2

S1

Day 3

Factor
Activin A
CHIR99021
Activin A
CHIR99021
No Feed

Concentration
100 ng/mL
14 µg/mL
100 ng/mL
None
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Company

Part Number

R&D Systems
Stemgent
R&D Systems

338-AC
04-0004-10
338-AC

Stage 2

Stage 3

Stage 4

Stage 5

Day 1
Day 2
Day 3

S2

Day 1

S3

Day 2

S3

S2

Day 1

S3

Day 2
Day 3

S3

Day 4
Day 5

S3

Day 1

BE5

Day 2
Day 3

KGF
No Feed
KGF

50 ng/mL

Peprotech

AF-100-19

50 ng/mL

Peprotech

AF-100-19

LDN193189
KGF
SANT1
PdBU
Y27632
RA
LDN193189
KGF
SANT1
PdBU
Y27632
RA

200nM
50 ng/mL
0.25 µM
500 nM
10 µM
2 µM
None
50 ng/mL
0.25 µM
500 nM
10 µM
2 µM

Thermo Fisher
Scientific
Peprotech
Sigma Aldrich
EMD Millipore
Abcam
Sigma Aldrich

NC0054000
AF-100-19
S4572
524390
ab120129
R2625

Peprotech
Sigma Aldrich
EMD Millipore
Abcam
Sigma Aldrich

AF-100-19
S4572
524390
ab120129
R2625

KGF
SANT1
Y27632
Activin A
RA
No Feed
KGF
SANT1
Y27632
Activin A
RA
No Feed
KGF
SANT1
Y27632
Activin A
RA

50 ng/mL
0.25 µM
10 µM
5 ng/mL
0.1 µM

Peprotech
Sigma Aldrich
Abcam
R&D Systems
Sigma Aldrich

AF-100-19
S4572
ab120129
338-AC
R2625

50 ng/mL
0.25 µM
10 µM
5 ng/mL
0.1 µM

Peprotech
Sigma Aldrich
Abcam
R&D Systems
Sigma Aldrich

AF-100-19
S4572
ab120129
338-AC
R2625

50 ng/mL
0.25 µM
10 µM
5 ng/mL
0.1 µM

Peprotech
Sigma Aldrich
Abcam
R&D Systems
Sigma Aldrich

AF-100-19
S4572
ab120129
338-AC
R2625

SANT1
RA
XXI
Alk5i

0.25 µM
0.1 µM
1 µM
10 µM

Sigma Aldrich
Sigma Aldrich
EMD Millipore
Axxora

S4572
R2625
595790
ALX-270-445-M005

T3
Betacellulin
No Feed
SANT1
RA
XXI
Alk5i

1 µM
20 ng/mL

EMD
Biosciences
R&D Systems

64245
261-CE-050

T3
Betacellulin

1 µM
20 ng/mL

0.25 µM
0.1 µM
1 µM
10 µM
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Sigma Aldrich
Sigma Aldrich
EMD
Millipore
Axxora
EMD
Biosciences

S4572
R2625
595790
ALX-270-445-M005
64245
261-CE-050

R&D Systems

Day 4
Day 5

Day 6
Day 7

Stage 6

EOD

S6

No Feed
SANT1
RA
XXI
Alk5i

None
25 nM
1 µM
10 µM

T3
Betacellulin

1 µM
20 ng/mL

No feed
SANT1
RA
XXI
Alk5i

None
25 nM
1 µM
10 µM

T3
Betacellulin

1 µM
20 ng/mL

Alk5i

10 µM

T3

1 µM

EOD: Feed every other day
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Sigma Aldrich
Sigma Aldrich
EMD
Millipore
Axxora
EMD
Biosciences
R&D Systems

S4572
R2625
595790
ALX-270-445-M005

Sigma Aldrich
Sigma Aldrich
EMD
Millipore
Axxora
EMD
Biosciences
R&D Systems

S4572
R2625
595790
ALX-270-445-M005

Axxora
EMD
Biosciences

ALX-270-445-M005

64245
261-CE-050

64245
261-CE-050

64245
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